CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $43.22M, above the global median of $16.24M
- FinancialsAltman Z-Score 6.12: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.00%Above 5Y avg (3.23%)
Annual Rate
KRW 1200.00Paid quarterly
Payout Ratio
77.1%Moderate
Payback Period
25.4 yr
Last Ex-Dividend
Jun 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.37TKRW967.84M · vs all stocks (USD)
Trailing P/E
28.65xvs Biotechnology peers
Revenue (TTM)
487.37BKRW345.08M · vs all stocks (USD)
Profit Margin
13.47%vs Biotechnology peers
Beta
0.8750xvs all stocks
52-Week Change
12.36%vs all stocks
Forward Annual Dividend Yield
4.00%vs all stocks
Market Capitalization
1.37TKRW967.84M · vs all stocks (USD)
Enterprise Value
987.14BKRW698.94M · vs all stocks (USD)
Trailing P/E
28.65xvs Biotechnology peers
Forward P/E
15.09xvs Biotechnology peers
PEG Ratio
1.37xvs Biotechnology peers
Price to Sales (TTM)
2.87xvs Biotechnology peers
Price to Book (MRQ)
1.34xvs Biotechnology peers
Enterprise to Revenue
2.02xvs Biotechnology peers
Enterprise to EBITDA
8.80xvs Biotechnology peers
Gross Margin
67.13%vs Biotechnology peers
Profit Margin
13.47%vs Biotechnology peers
Operating Margin
18.24%vs Biotechnology peers
Return on Assets (TTM)
2.17%vs Biotechnology peers
Return on Equity (TTM)
6.49%vs Biotechnology peers
Revenue (TTM)
487.37BKRW345.08M · vs all stocks (USD)
Revenue per Share (TTM)
10.58KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
11.30%vs Biotechnology peers
Gross Profit (TTM)
311.86BKRW220.81M · vs all stocks (USD)
EBITDA (TTM)
150.60BKRW106.63M · vs all stocks (USD)
Net Income (TTM)
65.66BKRW46.49M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
100.30%vs Biotechnology peers
Operating Cash Flow (TTM)
133.31BKRW94.39M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
61.04BKRW43.22M · vs all stocks (USD)
Forward Annual Dividend Rate
1.20KKRWUpdated Aug 19, 2026Forward Annual Dividend Yield
4.00%vs all stocks
Trailing Annual Dividend Rate
1.20KKRWUpdated Aug 19, 2026Trailing Annual Dividend Yield
4.00%vs all stocks
5-Year Average Dividend Yield
3.23%vs all stocks
Payout Ratio
77.08%vs Biotechnology peers
Minority Interest (Equity)
368.16MKRWFY2025 · Dec 31, 2025Revenue
474.23BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
170.37BKRWFY2025 · Dec 31, 2025Gross Profit
303.86BKRWFY2025 · Dec 31, 2025Operating Income
34.55BKRW24.46M · vs all stocks (USD)
Pre-tax Income
56.44BKRWFY2025 · Dec 31, 2025Income Tax Expense
7.99BKRWFY2025 · Dec 31, 2025Net Income
48.45BKRWFY2025 · Dec 31, 2025EBIT
60.90BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
133.99BKRWFY2025 · Dec 31, 2025Research & Development
66.26BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
80.87BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-354.98MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
13.71BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
4.47BKRWFY2025 · Dec 31, 2025EPS (Basic)
1.05KKRWFY2025 · Dec 31, 2025EPS (Diluted)
1.05KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
46.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
48.45BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-170.57MKRWFY2025 · Dec 31, 2025Operating Cash Flow
64.96BKRWFY2025 · Dec 31, 2025Free Cash Flow
27.83BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
225.57BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
48.45BKRWFY2025 · Dec 31, 2025Stock-based Compensation
768.13MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-9.52BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.11BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.38BKRWFY2025 · Dec 31, 2025Capital Expenditures
-37.14BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.11BKRWFY2025 · Dec 31, 2025Net Acquisitions
-8.19BKRWFY2025 · Dec 31, 2025Purchase of Investments
-647.68BKRWFY2025 · Dec 31, 2025Sale of Investments
562.28BKRWFY2025 · Dec 31, 2025Other Investing Activity
240.39MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-130.49BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-1.73BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-1.73BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-4.13BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-36.90BKRWFY2025 · Dec 31, 2025Other Financing Charges
-20.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-44.49BKRWFY2025 · Dec 31, 2025Shares Outstanding
45.56MSharesUpdated Aug 19, 2026Float Shares
30.51MSharesUpdated Aug 19, 2026% Held by Insiders
28.78%vs all stocks
% Held by Institutions
9.40%vs all stocks
Total Cash (MRQ)
607.10BKRW429.85M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.33KKRWUpdated Aug 19, 2026Total Debt (MRQ)
129.20BKRW91.48M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1263xvs Biotechnology peers
Current Ratio (MRQ)
4.46xvs Biotechnology peers
Book Value per Share (MRQ)
22.31KKRWUpdated Aug 19, 2026Total Assets
1.24TKRW874.99M · vs all stocks (USD)
Total Current Assets
798.78BKRWFY2025 · Dec 31, 2025Total Liabilities
219.98BKRWFY2025 · Dec 31, 2025Total Non-current Assets
437.02BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
49.23BKRWFY2025 · Dec 31, 2025Total Current Liabilities
170.75BKRWFY2025 · Dec 31, 2025Cash Equivalents
225.57BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
225.57BKRWFY2025 · Dec 31, 2025Other Short-term Investments
360.33BKRWFY2025 · Dec 31, 2025Accounts Receivable
97.59BKRWFY2025 · Dec 31, 2025Inventory
82.20BKRWFY2025 · Dec 31, 2025Accounts Payable
15.59BKRWFY2025 · Dec 31, 2025Short-term Debt
95.52BKRWFY2025 · Dec 31, 2025Other Current Liabilities
356.43MKRWFY2025 · Dec 31, 2025Long-term Debt
34.41BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-40.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
26.11BKRWFY2025 · Dec 31, 2025Retained Earnings
1.09TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.02TKRW719.24M · vs all stocks (USD)
Treasury Stock
196.75BKRWFY2025 · Dec 31, 202552-Week Low
21.70KKRWUpdated Aug 19, 202652-Week High
33.95KKRWUpdated Aug 19, 202652-Week Change
12.36%vs all stocks
Beta
0.8750xvs all stocks
50-Day MA
28.46KKRWUpdated Aug 19, 2026200-Day MA
26.19KKRWUpdated Aug 19, 2026Avg 10-Day Volume
347.65KSharesUpdated Aug 19, 2026Avg 30-Day Volume
274.32KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.05KKRWUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.12: safe zoneNotable
Altman Z-Score: 6.12
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $43.22M, above the global median of $16.24MNotable
Levered free cash flow (USD): 43,221,819.064Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bide Pharmatech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Skp Resources Berhad
1 interpretationRetained Earnings Heavy With Elevated Payout
Shanxi Lu'an Environmental Energy Development Co., Ltd.
1 interpretationRetained Earnings Heavy With Elevated Payout
FP Holdings, Inc.
1 interpretationRetained Earnings Heavy With Elevated Payout